ONO-4474 / Ono Pharma - LARVOL DELTA

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy Volunteers (clinicaltrials.gov) - P1; N=176; Recruiting; Sponsor: Ono Pharmaceutical Co. Ltd; Trial primary completion date: Jan 2016 ➔ Jun 2016

Trial primary completion date • Biosimilar • Osteoarthritis • Pain

Efficacy, Safety, and Tolerability of ONO-4474, an Orally Available Pan-Tropomyosin Receptor Kinase Inhibitor, in Japanese Patients with Moderate-to-Severe Osteoarthritis of the Knee: A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Study (ACR-ARHP 2018) - "ONO-4474 may be a tolerable and effective analgesic in patients with moderate-to-severe OA of the knee."

Clinical • Immunology

Efficacy, Safety, and Tolerability of ONO-4474, an Orally Available Pan-Tropomyosin Receptor Kinase Inhibitor, in Japanese Patients With Moderate to Severe Osteoarthritis of the Knee: A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Study. (PubMed, J Clin Pharmacol) - "Four patients from the ONO-4474 group and 1 patient from the placebo group discontinued treatment because of AEs; however, none were judged to be serious, and all patients recovered or were recovering after discontinuation. ONO-4474 is a novel tropomyosin receptor kinase inhibitor that has an analgesic effect in patients with OA."

Clinical • Journal